
## **Bernard Royer**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3056030/publications.pdf Version: 2024-02-01



| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anti-Cancer Drugs, 2005, 16, 1009-1016.   | 1.4 | 39        |
| 2  | A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1132, 121844. | 2.3 | 34        |
| 3  | Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World Journal of Surgical Oncology, 2009, 7, 14.   | 1.9 | 30        |
| 4  | An APCI LCâ€MS/MS method for routine determination of capecitabine and its metabolites in human plasma. Journal of Mass Spectrometry, 2010, 45, 670-677.  | 1.6 | 29        |
| 5  | Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemotherapy and Pharmacology, 2008, 61, 415-421.  | 2.3 | 22        |
| 6  | Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anti-Cancer Drugs, 2006, 17, 1211-1217.   | 1.4 | 18        |
| 7  | Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study. Anti-Cancer Drugs, 2010, 21, 320-325.  | 1.4 | 13        |
| 8  | Level of evidence for therapeutic drug monitoring of taxanes. Fundamental and Clinical Pharmacology, 2011, 25, 414-424.   | 1.9 | 12        |
| 9  | Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration. Clinical Pharmacokinetics, 2009, 48, 169-180.  | 3.5 | 11        |
| 10 | Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients.<br>Pharmaceutics, 2021, 13, 1708.   | 4.5 | 8         |
| 11 | Level of evidence for therapeutic drug monitoring for etoposide after oral administration.<br>Fundamental and Clinical Pharmacology, 2011, 25, 277-282.   | 1.9 | 5         |
| 12 | Exposureâ€response analysis of Raltitrexed assessing liver toxicity. British Journal of Clinical<br>Pharmacology, 2021, 87, 1327-1337.  | 2.4 | 5         |
| 13 | Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 156, 199-203.   | 1.1 | 4         |
| 14 | Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients. Cancer Chemotherapy and Pharmacology, 2021, 87, 229-239.   | 2.3 | 4         |
| 15 | Population Pharmacokinetics of Palbociclib in a Real-World Situation. Pharmaceuticals, 2021, 14, 181.   | 3.8 | 4         |
| 16 | A simple and fast LC–MS/MS method with a very high sensitivity for the measurement of raltitrexed in<br>human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life<br>Sciences, 2017, 1060, 240-246.   | 2.3 | 3         |
| 17 | Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian<br>Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients. Annals of Surgical<br>Oncology, 2022, 29, 3322-3334.  | 1.5 | 3         |
| 18 | The Authors' Reply. Clinical Pharmacokinetics, 2009, 48, 686-687.   | 3.5 | 0         |